日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study

LYSA 研究通过对 1280 例参与临床试验的套细胞淋巴瘤患者进行分析,验证了 POD24 作为套细胞淋巴瘤早期预后不良的可靠临床指标的有效性。

Sarkozy, Clémentine; Chartier, Loïc; Ribrag, Vincent; Gressin, Remy; Geisler, Christian H; Kluin-Nelemans, Hanneke C; Thieblemont, Catherine; Morschhauser, Franck; Lemonnier, François; Safar, Violaine; Tessoulin, Benoît; Oberic, Lucie; Damaj, Ghandi; Ghesquières, Hervé; Bouabdallah, Krimo; Casasnovas, René Olivier; Houot, Roch; Klapper, Wolfram; Burroni, Barbara; Pott, Christiane; Delfau-Larue, Marie-Hélène; Macintyre, Elizabeth; Callanan, Mary; Jerkeman, Mats; Unterhalt, Michael; Hoster, Eva; Dreyling, Martin; Le Gouill, Steven; Hermine, Olivier; Cheminant, Morgane

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance

德国淋巴瘤联盟开展的一项II期研究结果显示,伊布替尼联合奥妥珠单抗治疗未经化疗的晚期滤泡性淋巴瘤疗效显著。

Schmidt, Christian; Scheubeck, Gabriel; Jurinovic, Vindi; Sökler, Martin; Forstpointner, Roswitha; Buske, Christian; Viardot, Andreas; Keller, Ulrich; Graeven, Ullrich; Marks, Reinhard; Hänel, Mathias; Liersch, Rüdiger; Dürig, Jan; Pott, Christiane; Hoster, Eva; Unterhalt, Michael; Hiddemann, Wolfgang

Erratum to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance"

更正:“伊布替尼和奥妥珠单抗联合治疗未经治疗的晚期滤泡性淋巴瘤:德国淋巴瘤联盟 II 期研究的结果”

Schmidt, Christian; Scheubeck, Gabriel; Jurinovic, Vindi; Sökler, Martin; Forstpointner, Roswitha; Buske, Christian; Viardot, Andreas; Keller, Ulrich; Graeven, Ullrich; Marks, Reinhard; Hänel, Mathias; Liersch, Rüdiger; Dürig, Jan; Pott, Christiane; Hoster, Eva; Unterhalt, Michael; Hiddemann, Wolfgang

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment

MCL老年患者III期试验方案:一项国际性、随机、开放标签的II期临床试验,旨在研究维奈托克、伊布替尼和利妥昔单抗联合用药或苯达莫司汀、伊布替尼和利妥昔单抗联合用药治疗不适合接受高剂量治疗的初治套细胞淋巴瘤患者的疗效。

Herold, Stephanie; Schmidt, Christian; Visco, Carlo; Tilch, Marie-Kristin; Ohler, Anke; Unterhalt, Michael; Hoster, Eva; Hoenig, Elisabeth; Singer, Susanne; Tucci, Alessandra; Pott, Christiane; Ladetto, Marco; Hess, Georg; Dreyling, Martin

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network

在复发或难治性套细胞淋巴瘤中,利妥昔单抗、大剂量阿糖胞苷和地塞米松联合硼替佐米治疗——欧洲套细胞淋巴瘤网络的一项随机、开放标签III期试验

Fischer, Luca; Jiang, Linmiao; Dürig, Jan; Schmidt, Christian; Stilgenbauer, Stephan; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W; Feugier, Pierre; de Wit, Maike; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen; Giagounidis, Aristoteles A N; Dargel, Beate; Durot, Eric; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver; Pott, Christiane; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva; Ribrag, Vincent; Dreyling, Martin

Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group

利妥昔单抗、吉西他滨和奥沙利铂治疗复发或难治性惰性淋巴瘤和套细胞淋巴瘤:德国低级别淋巴瘤研究组一项多中心I/II期研究的结果

Scheubeck, Gabriel; Hoffmann, Martin; Jurinovic, Vindi; Fischer, Luca; Unterhalt, Michael; Schmidt, Christian; Böck, Hans-Peter; Dührsen, Ulrich; Kaesberger, Joachim; Kremers, Stephan; Lindemann, Hans-Walter; Mantovani, Luisa; Hiddemann, Wolfgang; Hoster, Eva; Dreyling, Martin

Polarization-Dependent Sum-Frequency-Generation Spectroscopy for In Situ Tracking of Nanoparticle Morphology

用于原位追踪纳米颗粒形貌的偏振相关和频光谱

Pramhaas, Verena; Unterhalt, Holger; Freund, Hans-Joachim; Rupprechter, Günther

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

高危套细胞淋巴瘤患者(高危 MIPI-c 或高 p53 表达)的临床结果

Scheubeck, Gabriel; Jiang, Linmiao; Hermine, Olivier; Kluin-Nelemans, Hanneke C; Schmidt, Christian; Unterhalt, Michael; Rosenwald, Andreas; Klapper, Wolfram; Evangelista, Andrea; Ladetto, Marco; Jerkeman, Mats; Ferrero, Simone; Dreyling, Martin; Hoster, Eva

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis

利妥昔单抗联合化疗可提高套细胞淋巴瘤患者的总生存期——一项汇总试验分析

Fischer, Luca; Jiang, Linmiao; Bittenbring, Joerg Thomas; Huebel, Kai; Schmidt, Christian; Duell, Johannes; Metzner, Bernd; Krauter, Juergen; Glass, Bertram; Huettmann, Andreas; Schaefer-Eckart, Kerstin; Silkenstedt, Elisabeth; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Dreyling, Martin; Hoster, Eva

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma

适合移植的套细胞淋巴瘤患者接受苯达莫司汀或高剂量阿糖胞苷联合利妥昔单抗诱导治疗

Villa, Diego; Hoster, Eva; Hermine, Olivier; Klapper, Wolfram; Szymczyk, Michal; Bosly, André; Unterhalt, Michael; Rimsza, Lisa M; Ramsower, Colleen A; Freeman, Ciara L; Scott, David W; Gerrie, Alina S; Savage, Kerry J; Sehn, Laurie H; Dreyling, Martin